Affordable Access

deepdyve-link
Publisher Website

[Definitive or neo-adjuvant chemoradiation in esophageal carcinoma?]

Authors
  • Modesto, A1
  • Carrère, N2
  • Guimbaud, R3
  • Rives, M4
  • Deutsch, É5
  • Quéro, L6
  • Créhange, G7
  • 1 Département de radiothérapie, institut Claudius-Regaud, Institut universitaire du cancer de Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France. Electronic address: [email protected] , (France)
  • 2 Département de chirurgie digestive, centre hospitalier universitaire de Toulouse-Rangueil, 1, avenue Jean-Poulhès, 31000 Toulouse, France. , (France)
  • 3 Département d'oncologie digestive, centre hospitalier universitaire de Toulouse-Rangueil, 1, avenue Jean-Poulhès, 31000 Toulouse, France. , (France)
  • 4 Département de radiothérapie, institut Claudius-Regaud, Institut universitaire du cancer de Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France. , (France)
  • 5 Département d'oncologie radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France. , (France)
  • 6 Service de cancérologie-radiothérapie, pôle Icare, hôpital Saint-Louis, AP-HP.7, 1, avenue Claude-Vellefaux, 75010 Paris, France. , (France)
  • 7 Service de radiothérapie, centre Georges-François-Leclerc, 1, rue Professeur-Marion, BP 77 980, 21079 Dijon cedex, France. , (France)
Type
Published Article
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Publication Date
Aug 14, 2019
Identifiers
DOI: 10.1016/j.canrad.2019.06.010
PMID: 31421997
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

Management of resectable esophageal carcinoma is based on a multimodal treatment associating neo-adjuvant chemoradiation before surgery. This therapeutic sequence allows a disease-free survival rate at 2 years around 45% but remains associated with a high post-operative morbidity. In case of definitive chemoradiotherapy, the dose delivered to the macroscopic disease is a controversial topic since decades and the prognosis of patients treated in this setting at the dose of 50Gy remains poor. This article proposes a review of the main published data and the ongoing studies related to the management of these patients. Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times